(BioViva USA Inc) BioViva USA is funding Hua Zhu’s research team at Rutger’s University to develop an aging vaccine that will deliver several anti-aging and regenerative factors. The short-term goal is to extend the lifespan of primary human cells and aged mice. The long-term goal is to establish a platform for clinical trial studies using a novel virus as a vaccine vector to develop a multi-gene therapeutic aging vaccine.